Initial Egyptian ECMO experience  by Abdelbary, Akram et al.
The Egyptian Journal of Critical Care Medicine (2016) 4, 25–32The Egyptian College of Critical Care Physicians
The Egyptian Journal of Critical Care Medicine
http://ees.elsevier.com/ejccm
www.sciencedirect.comORIGINAL ARTICLEInitial Egyptian ECMO experience* Corresponding author.
Peer review under responsibility of The Egyptian College of Critical Care Physicians.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.ejccm.2016.01.005
2090-7303  2016 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. All rights reserved.Akram Abdelbary a,*, Mohamed Khaled a, Wael Sami a, Ahmed Said a,
Mohamed Yosri a, Mohamed Abuelwafa a, Mahmoud Saad a, Hani Tawfik a,
Ibrahim Zoghbi a, Mohamed Abouelgheit a, Ahmed Rostom a, Walid Shehata a,
Ahmed Mostafa a, Soliman Bilal a, Ahmed Hares a, Dina Zeid a, Mohamed Saad a,
Karim Zaki a, Hosam Abdelwahab a, Khaled Hamed a, Mohamed Ali a,
Abdalla Yusuf a, Amany AbuZeid b, Mohamed Mostafa b, Tarek Mohsen c,
Mohamed Sewelam c, Ahmed Elsharkawy c, Yasser Abdelwahab d, Alia Abdelfattah aaCritical Care Department, Faculty of Medicine, Kasr ElAini, Cairo University, Egypt
bChest Department, Faculty of Medicine, Kasr ElAini, Cairo University, Egypt
cCardiothoracic Surgery Department, Faculty of Medicine, Kasr ElAini, Cairo University, Egypt
dAnaesthesia Department, Faculty of Medicine, Kasr ElAini, Cairo University, EgyptReceived 22 January 2016; accepted 31 January 2016
Available online 2 March 2016Abstract Introduction: Extracorporeal membrane oxygenation (ECMO) is considered a rescue
therapy in severe cases of acute cardiac and or respiratory failure.
Aim of the work: We describe our initial experience at the first ECMO center in Egypt.
Methods: Our adult ECMO program started in January 2014. Since then we supported eleven
respiratory failure patients on ECMO indicated according to ELSO guidelines and one case of
ECMO CPR. Respiratory failure patients were subjected to VV ECMO when lung injury score
(LIS) was above 3 and PaO2/FiO2 <100 on protective lung strategy mechanical ventilation accord-
ing to ARDS net protocol and or severe hypercapnia with pH < 7.2 with trial of prone positioning
in the indicated cases. Percutaneous cannulation was done in all patients using single lumen cannu-
lae, additional cannula was added when needed. Cardiohelp (Maquet, Germany) and Rotaflow
(Maquet, Germany) ECMO consoles were used with centrifugal pump. ECMO circuits PLS for
Rotaflow and HLS for Cardiohelp were changed when indicated. The ECMO CPR patient was
a primary PCI for acute inferior STEMI complicated by left main occlusion, VA ECMO instituted
in the cath-lab after 20 min of CPR. Percutaneous (and or surgical) tracheostomy was done after
14 days of mechanical ventilation.
Table 1 ECMO cases.
VV ECMO cases Indications
H1N1 Refractory hyp
Vasculitis Refractory hyp
Bacterial pneumonia
(4 cases)
Refractory hyp
hypercapnia
Traumatic lung (2
cases)
Refractory hyp
Organophosphorus Refractory hyp
Undiagnosed Refractory hyp
a NA: not applicable.
26 A. Abdelbary et al.Results: A total of twelve patients received ECMO between January 2014 and June 2015. The
mean age was 35.9 years. (range 13–65 years), 8 males, with VV ECMO in 10 patients, and VA
ECMO in 2 patients. Out of ten patients of VV ECMO, one had H1N1 pneumonia, one had
advanced vasculitic lung, four had bacterial pneumonia, two traumatic lung contusions and one
with organophosphorus poisoning, and one undiagnosed etiology leading to severe ARDS. Lung
injury score range was 3–3.8, PaO2/FiO2 (20–76) mechanical ventilation duration before ECMO
1–14 days, Femoro-jugular cannulation in 7 patients and femoro-femoral in 2 patients and
femoro-subclavian in 1 patient; all patients were initially sedated and paralyzed for (2–4 days)
and ventilated on pressure controlled ventilation with Pmax of 25 cm H2O and PEEP of 10 cm
H2O. In VA ECMO patients were cannulated percutaneously using femoro-femoral approach.
One patient showed no neurologic recovery and died after 24 h, the other had CABG on ECMO
however the heart didn’t recover and died after 9 days. Heparin intravenous infusion was used ini-
tially in all patients and changed to Bivalirudin in 2 patients due to possible HIT. Pump flow ranged
from 2.6 to 6.5 L/min. Average support time was 12 days (range 2–24 days). Seven patients (63.3%)
were successfully separated from ECMO and survived to hospital discharge. Hospital length of stay
ranged from 3 to 42 days, tracheostomy was done percutaneously in 5 patients and surgically in 3.
Gastrointestinal bleeding occurred in 6 patients, VAP in 7 patients, neurologic complications in 1
patient with complete recovery, cardiac arrhythmias in 3 patients, pneumothorax in 9 patients, and
deep venous thrombosis in 2 patients.
 2016 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Acute respiratory distress syndrome (ARDS) is a disease
affecting the lungs secondary to primary pulmonary or extra-
pulmonary causes [1]. It was first described by Ashbaugh
and colleagues in 1967 [2]. The disease is characterized as an
acute diffuse inflammatory lung injury leading to increased
pulmonary vascular permeability and lung weight and loss of
aerated lung tissue [1]. Alveolar filling affects proper oxygena-
tion in addition to carbon dioxide removal in severe forms [3].
Based on the degree of hypoxemia, ARDS was categorized
with correlation to mortality (Table 1) [3]. Severe ARDS char-
acterized by Pa2/FiO2 <100 is a challenging condition in the
medical field especially to critical care physicians. Many venti-
latory and non ventilatory strategies were studied and appliedMV before
ECMO
MUR
score
oxia 3 3.75
oxia 3 NAa
oxia and 14 3.75
4 3.25
4 3.5
4 3.25
oxia 1 3.5
3 3.75
oxia 3 3.75
oxia 2 3.75in the last decade that resulted in reducing mortality [4]; this
was mainly achieved through changing mechanical ventilation
strategy that resulted in decreasing ventilator induced lung
injury (VILI) [5,6]. However despite these strategies, mortality
is still high in severe ARDS [3].
Extracorporeal membrane oxygenation (ECMO) is not a
newly developed technique. The main aim of ECMO develop-
ment was trying to maintain tissue oxygenation through
bypassing the lungs when other strategies fail. The theory
was to develop a membrane lung that can withstand hydro-
static pressure and is permeable to gas exchange. The first
developed silicon rubber membrane was by Kemmermeyer
in 1957 [7] then in 1968, Kolobow and Zapol developed the
first membrane oxygenator that can withstand prolonged
operation [8].RAY Resp.
score
PaO2/
FiO2
ECMO run
duration
Hospital
LOS
Survival
5 70 21 44 Survived
3 70 13 22 Died
8 20 22 27 Died
1 70 23 33 Died
5 80 14 20 Survived
5 50 7 30 Survived
1 60 9 39 Survived
2 60 12 27 Survived
3 70 6 28 Survived
6 50 13 26 Survived
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many challenges over the years. The first challenge was the
mode of bypass in respiratory failure which changed from
Veno-Arterial (VA) to Veno-venous (VV) sparing a lot of
potentially life threatening complications, the second chal-
lenge was the associated coagulopathy [9,10] as coagulation
system activation occurs immediately after contact with the
non-biological surface of ECMO unit leading to tissue factor
activation [11–13]. Platelet adhesion and activation occurs
upon exposure to the circuit resulting in thrombocytopenia
and thrombasthenia [14,15]. Bleeding occurred secondary to
massive anticoagulation use to prevent thrombosis of the
older huge membrane lungs with consequent need for mas-
sive blood transfusion [16]. The third was hemolysis created
by prolonged use of the roller pump which dramatically
improved after the development of the centrifugal pump
achieving higher flow with less hemolysis over time [17,18],
the fourth was the shift from thrombogenic and
inflammatory-inducing circuits to heparin coated and bio-
compatible circuits that need less anticoagulation (with con-
sequent less bleeding) [19–21], and the fifth, was the
miniaturizing of ECMO consoles that allowed ECMO retrie-
val [22]. Perhaps the most important challenge was the lack
of randomized control trials to show superiority of ECMO
over standard therapy. This was first established in neonates
in 1996 by demonstrating the beneficial role of ECMO in
neonatal respiratory distress syndrome [23]. In adults the
proof of concept needed many years till finally the publishing
of CESAR trial in 2009 showing significant survival benefit
in severe ARDS patients transferred to an ECMO center
when compared to receiving standard therapy in their Inten-
sive care units [24].
The H1N1 epidemic in 2009 resulted in the expansion of
ECMO use in developed countries. According to the ELSO
registry the use of ECMO has steadily increased with obvious
growth in years 2009 through 2011 [25]. Lung pathology in
proven H1N1 patients was mainly diffuse alveolar damage,
with two other pathology patterns of necrotizing bronchiolitis
and extensive pulmonary hemorrhage [26]. There were three
published registries, one in UK [27], a second in New
Zealand–Australia [28] and a third in France [29]. All these
recent publications have suggested a potential survival benefit
with ECMO use; however, none of them achieved the solid
proof of concept about the value of ECMO in ARDS. The cur-
rently ongoing EOLIA randomized multicenter trial may
answer this question [30].
VILI in ARDS patients has been described by several
authors and demonstrated in experimental studies [31,32]. Fur-
ther studies established the pivotal role of high volume lung
ventilation and importance of the level of plateau pressure in
the development of VILI [33,34]. However, in severe cases
the physicians have no choice but to use high PEEP and
recruitment maneuvers to maintain oxygenation [5,35,36] with
subsequent potentially deleterious effects on the lungs and
uncertain benefit, especially with low recruitment potentials
in addition to hemodynamic instability [35]. In severe cases
the use of recommended low tidal volumes may result in hyper-
capnia with consequent pulmonary hypertension and the
potential to develop acute cor-pulmonale leading to high
mortality rates [37,38]. The use of complete sedation andparalysis has been demonstrated to lead to diaphragmatic
myopathy and respiratory muscle weakness [39,40].
The concept of using ECMO to allow ultra-protective ven-
tilation or lung rest may lead to the shortening of ventilation
and better healing of the lungs (but this remains to be proved).
Bypassing mechanical ventilation in these cases with awake
ECMO may be a target in the near future [41,42].
ECMO was recently introduced to the Middle East
especially the gulf countries. Introduction of ECMO to Egypt
was quite challenging with economic obstacles and lack of
trained personnel in addition to the lack of convincing data.
2. Patients and methods
This study included all patients connected to ECMO from Jan-
uary 2014 till September 2015. The initial ECMO set up was in
a single room in the department with air fluidized bed.
Upon arrival to our center all patients were subjected to
detailed history of comorbidities, current illness including
onset, duration, progression, investigations and treatments
received. Murray lung injury score (LIS) for all patients was
calculated using four parameters: [43] number of quadrants
with consolidation in chest X-ray, PaO2/FiO2 in mmHg,
Positive end expiratory pressure in cm H2O, and Compliance
in ml/cm H2O.
The score range from 1 to 4, and score above 3 represented
severe ARDS with expected high mortality.
The Respiratory Extracorporeal Membrane Oxygenation
Survival Prediction (RESP) score for all respiratory patients
to determine the probability of survival on ECMO, is calcu-
lated on line in the website www.respscore.com [44] (Table 1).Age, years18–49 050–59 2
P60 3Immunocompromised status* 2
Mechanical ventilation prior to initiation of ECMO<48 h 348 h to 7 d 1>7 d 0Acute respiratory diagnosis group (select only one)Viral pneumonia 3Bacterial pneumonia 3Asthma 11Trauma and burn 3Aspiration pneumonitis 5Other acute respiratory diagnoses 1Non-respiratory and chronic respiratory diagnoses 0Central nervous system dysfunctiony 7
Acute associated (non-pulmonary) infection 3
Neuromuscular blockade agents before ECMO 1Nitric oxide use before ECMO 1
Bicarbonate infusion before ECMO 2
Cardiac arrest before ECMO 2
PaCO2 , mm Hg<75 0P75 1
Peak inspiratory pressure, cm H2O<42 0P42 1
Total score 22 to 15
28 A. Abdelbary et al.Hospital survival by risk classTotal RESP Score Risk class SurvivalP6 I 92%
3–5 II 76%1 to 2 III 57%
5 to 2 IV 33%
66 V 18%
(Table 1) RESP score: ECMO= extracorporeal membrane
oxygenation; RESP= Respiratory ECMO Survival Prediction.
*‘‘Immunocompromised” is defined as hematological malignancies,
solid tumor, solid organ transplantation, human immunodeficiency
virus, and cirrhosis.
y‘‘Central nervous system dysfunction” diagnosis combined neuro-
trauma, stroke, encephalopathy, cerebral embolism, and seizure
and epileptic syndrome.
‘‘Acute associated (non-pulmonary) infection” is defined as
another bacterial, viral, parasitic, or fungal infection that did not
involve the lung.
The procedure and technique with potential complications
were explained to the patients’ guardians and an informed wit-
nessed consent was obtained from the first degree relative
before the initiation of therapy.
2.1. VV ECMO indications
Patients were considered for VV ECMO based on the criteria
of ELSO organization; Refractory hypoxemia despite lung
protective strategy according to ARDS rent protocol, severe
respiratory academia with pH <7.25, and Murray lung injury
score 3–4.
2.2. Exclusion criteria
Respiratory patients not fulfilling the indications are: Patients
who are brain dead or didn’t recover neurologically after the
history of cardiopulmonary arrest, patients with terminal
malignancy, patients with marked hemodynamic instability
(septic shock) and multi-organ failure, patients older than
65 years, patients with prolonged mechanical ventilation
>14 days, and patient relatives refusing ECMO treatment.
2.3. Cannulation
2.3.1. VV ECMO cases
All patients were cannulated percutaneously, using standard
Seldinger technique Maquet Venous and arterial cannulae
were used in 11 patients and Medtronic cannulae were used
in 2 patients. All cannulae positions were confirmed by Echo
after implantation and by bedside chest X-ray.
Positions were modified according to the chest X-ray’s pres-
ence of abnormal position or hemodynamically significant
recirculation.
Femoro-jugular approach was attempted initially in 9
patients and was successful in 7 patients. One patient had
Femoro-subclavian. Two patients had femoro-femoral.
2.3.2. VA ECMO cases
All patients were cannulated percutaneously, using standard
Seldinger technique Maquet Venous and arterial cannulaewere used in both patients. Cannulation was done in the
cath-lab under image guidance, drainage cannula from femoral
vein and arterial cannula in the femoral artery.
2.4. Consoles
We have the centrifugal pump systems including the poly-
methylpentene membrane from Maquet. The two available
consoles were Cardiohelp and Rotaflow. The flow that can
be achieved is 7 l/minute for the Cardiohelp and 8 l/m for
the Rotaflow. The Cardiohelp is more compact and suitable
for patient transportation. The pump and oxygenator are uni-
fied in the Cardiohelp and separate in the Rotaflow. Both con-
soles allow monitoring of flow and rounds per minute. Both
have bubble detectors as well. The Cardiohelp console has a
screen display that allows monitoring of SvO2, Hemoglobin,
hematocrit, and pressures before, intra and after the oxygena-
tor/pump unit. The Cardiohelp console allows storage of
ECMO run data and data transfer in addition to different
operation modality programs for VA, VV, PALP and rota-
assist.
2.5. Mechanical ventilation
2.5.1. In VV ECMO cases
Ultraprotective lung strategy; pressure controlled ventilation
with peak airway pressure set to 25 cm H2O and PEEP to
10 cm H2O. Patients were shifted to pressure support ventila-
tion after the discontinuation of sedation.
2.5.2. In VA ECMO
Mechanical ventilation was adjusted to decrease the work of
breathing and to achieve Right hand Oxygen saturation
>90%.
2.6. Anticoagulation
A bolus of 80 IU/kg is given initially after cannulation is com-
pleted followed by Heparin intravenous infusion to keep aPTT
1.5 times the baseline usually 50–70 s. Bivalirudin is given if
severe thrombocytopenia with a suspected HIT dose of
0.1 mg/kg/hour. Anticoagulation was discontinued in cases
of major bleeding and reversal of heparin given only if the
bleeding did not stop after the discontinuation of heparin.
Other measures as fresh frozen plasma transfusion, vitamin
K, tranexamic acid and activated factor VII were given as indi-
cated and according to the laboratory patient data only in
massive uncontrollable bleeding.
2.6.1. ECMO weaning
We initiated weaning when patients fulfilled the following cri-
teria; 1 – improvement of lung mechanics which is marked by
improving compliance and tidal volume, 2 – evident radiologic
improvement in the form of starting lung aeration, 3 – need for
less ECMO flow to achieve adequate oxygenation, 4 – with-
stands a weaning trial in the form of decreasing ECMO FiO2
to 0.21 for 1 h with ventilator FiO2 <0.6.
Weaning starts by keeping the ECMO flow at 3 l/m at least
on ECMO FiO2 of 0.21 for at least 12 h and ventilator FiO2
<0.6, PEEP 10 cm H2O, and pressure support of 15 cm H2O.
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manual compression on the cannulation site for 30 min.
2.7. Laboratory investigations: for coagulation monitoring
Fibrinogen and aPTT Q 6 h NR daily.
2.8. Other procedures
Tracheostomy: performed percutaneously or surgically
between day 10 and 14 after mechanical ventilation.
3. Results
A total of twelve patients received ECMO between January
2014 and June 2015.
The mean age was 35.9 years (range 13–65 years), 7 Males,
with VV ECMO in 10 patients, and VA ECMO in 2 patients.
3.1. VV ECMO cases
Out of ten patients of VV ECMO, one had H1N1 pneumonia,
One had advanced vasculitic lung, four had bacterial pneumo-
nia, two traumatic lung contusions and one organophosphorus
poisoning, and one undiagnosed etiology leading to severe
ARDS (Fig. 1).
Nine patients had ARDS complicating the original respira-
tory illness. The LIS ranged from 3 to 3.8 in those patients.
One patient had refractory hypoxemia secondary to severe vas-
culitic lung disease. The PaO2/FiO2 ratio ranged from 20 to 76
(Table 1).
3.2. ECMO management and complications
Pump flow ranged from 2.6 to 6.5 L/min. Average support
time was 12 days (range 2–24 days). B blockers were given in
5 patients, Ivabradine was given in 4 patients and packed red
cell transfusions were given in all patients to improve oxygen
delivery in cases needing high ECMO flow. Seven patients
(63.3%) were successfully weaned off ECMO and survived to
hospital discharge. Hospital length of stay ranged from 3 toH1N1
Vasculis
Bacterial
organophospho
rus
trauma
undiagnosed
RESPIRATORY
CASES DIAGNOSIS
Figure 1 Respiratory cases according to diagnosis.42 days, tracheostomy was done percutaneously in 5 patients
and surgically in 3. Gastrointestinal bleeding occurred in 6
patients and was managed conservatively using intravenous
proton pump inhibitors and temporary interruption of antico-
agulation which ranged from 2 to 5 days. Ventilator associated
pneumonia occurred in 7 patients. Neurologic complications
developed in 1 patient which was small non hemorrhagic
fronto-parietal infarction discovered due to prolonged disori-
entation after sedation vacation with lateralization on con-
tralateral upper and lower limbs. This patient regained full
consciousness level and motor power improved. Cardiac
arrhythmias occurred in 3 patients all were atrial fibrillation
two all of them were defibrillated and maintained on amio-
darone, pneumothorax in 9 patients, and deep venous throm-
bosis in 2 patients (Table 2).
3.3. VA ECMO cases
In the first VA ECMO case the patient was cannulated during
CPR, femoro-femoral percutaneous approach. The patient
showed no neurologic recovery and died after 24 h. The second
VA ECMO case was a cardiogenic shock patient presenting
with inferior STEMI coronary angiography showed severe
multi-vessel disease attempted primary PCI failed and the
patient was connected to ECMO and stabilized. CABG was
done on ECMO after 24 h and the patient survived for 9 days
with no myocardial recovery despite use of dobutamine and
levosimendan. The course was complicated by occipital non
hemorrhagic cerebral infarction and lower limb ischemia.
The patient died due to refractory arrhythmias and asystole
(Table 3).
3.4. Anticoagulation
Heparin intravenous infusion was used initially in all patients
and changed to Bivalirudin in 2 VV ECMO patients due to
possible HIT, with no bleeding or thrombotic complications
related to Bivalirudin, and a significant rise in platelet count
in next 48 h.
4. Discussion
ECMO technology is now playing an important role in critical
care. In spite of not being a health care priority in Egypt, theTable 2 Respiratory cases complications.
Complications Number Percent
Oxygenator clotting 1 10
Gastro-intestinal bleeding 6 60
Cannula site bleeding 1 10
Continuous renal replacement therapy 1 10
Inotropes 1 10
Myocardial stunning 1 10
Cardiac arrhythmias 3 20
Hypertension requiring vasodilators 1 10
Pneumothorax 5 50
VAP 7 70
Critical Illness neuropathy–myopathy 5 50
Neurological deficits 1 10
Table 3 VA ECMO cases.
VA ECMO cases Indications Lactate ECMO run duration Complications Survival
Anterior STEMI ECMO CPR 7 24 h Cerebral anoxia Died
Inferior STEMI Cardiogenic shock 11 9 days CVS lower limb ischemia Died
30 A. Abdelbary et al.introduction of ECMO carries many scientific medical and
strategic goals.
The Critical Care Department, Cairo University, founded
in 1982 introduced the specialty to the medical community
and took the lead in introducing many medical strategies
and technologies related to this specialty since then. Introduc-
tion of ECMO through the department not only raised the
enthusiasm in the whole country in specialty of Critical care
but also added to the available technologies in the country.
In the Critical care Department, Cairo University with lim-
ited resources and the help of donations the first successful
ECMO unit was created in June 2013. In 24th January 2014
the first ARDS case was connected to VVECMO and success-
fully weaned on 13th February 2014.
The results of our center are benchmarked against the
ELSO registry results with rather acceptable results in VV
ECMO outcome with overall survival of 58% in adult respira-
tory ECMO cases [62].
Proper selection of patients is still the main determinant of
outcome. The patients who died represented a category already
with calculated poor outcome as seen by their very low RESP
scores.
Most of our respiratory cases fulfilled the criteria of severe
ARDSwith refractory hypoxemia that can benefit from ECMO
support [1,3,24,34]. Patients were ventilated according to
ARDS net [45] protocol with low tidal volume 4–6 ml/kg/breath
PEEP was increased incrementally while the patients were
sedated and paralyzed [46] and following increase in FiO2 reach-
ing 100% inhaled oxygen, the peak inspiratory pressure was set
to keep plateau pressure maximum of 35 cm H2O [45]. Steroids
were tested in several studies [47]. All patients received steroids
with a protocol similar toMeduri et al. withmethylprednisolone
1 mg/kg/24 h with slight benefit as regards ventilation and
length of stay [48]. Inhaled nitric oxide is one of the non-
ventilator strategies in severe ARDS however has doubtful sur-
vival benefit [6] and was not used in any of our patients due to
unavailability in Egypt. Prone positioning showed in a recent
publication a survival benefit when applied for prolonged peri-
ods of time and was tried in some cases.
Veno-venous femoro-jugular percutaneous [49,50] cannula-
tion approach was shown to be better than jugulo-femoral
approach in these two studies and the distance of more than
15–20 cm between both cannulae favors less recirculation
[50]. This was our initial approach tried in most patients unless
there were anatomical barriers (one patient had bifurcating
internal jugular vein another had massive surgical emphysema
in the upper part of the body) or failed jugular route (one
patient).
We followed the ultraprotective mechanical ventilation
strategy demonstrated by Brodie [51]. Sedation and paralysis
were continued to decrease respiratory work of breathing
and avoid swing in pressures with spontaneous breathing; as
recommended by the ACURASYS trial we used atracurium
infusion and sometimes pancuronium boluses [46]. Pressuresupport ventilation was resumed as early as possible to avoid
ventilator induced diaphragmatic dysfunction [34,51]. Despite
this strategy most of the patients developed barotrauma which
reflects the very low compliance of the lungs [52].
We sometimes used B-blockers or Ivabradine to decrease
heart rate and cardiac output and improve oxygenation as a
last step after increasing pump flow, control of fever and
Packed red cell transfusions usually this resulted in decreasing
the flow needed to achieve adequate oxygenation however we
cannot deduce a conclusion from this small number of
patients. Several studies have demonstrated the efficacy of this
approach [53,54]. Packed RBCS transfusion was used in sev-
eral studies to improve oxygenation using lower pump flow
rates in cases with relative hypoxia on ECMO decreasing
hemolysis [18,55,56].
We started weaning from ECMO without decreasing the
flow below 3 l/m to avoid thrombosis of the circuit, our trial
lasted for 24 h before decannulation and none of our patients
needed resumption of support after decannulation. We experi-
enced one oxygenator thrombosis during a planned weaning
trial and the patient was decannulated [57].
Bleeding complications on ECMO may be secondary to
anticoagulation, heparin induced thrombotic thrombocytope-
nia or circuit induced fibrinolysis and consumption coagulopa-
thy [58], other causes may include acquired von Willebrand
syndrome and dilution of coagulation factors [58,59].
Bleeding on ECMO is usually managed conservatively with
PRBCs transfusion, platelet transfusion as needed and some
reports showed benefits of giving tranexamic acid intravenously,
surgical bleeding should receive surgical hemostatic measures
[60]. With new heparin coated circuits it is possible to interrupt
anticoagulation for hours or days [61]. In our patients we had
life threatening pulmonary hemorrhage in a vasculitic lung
patient who received; Protamine sulfate, tranexamic acid, fresh
plasma, vitamin K, PRBCs and activated factor VII. Other
patients needed just the discontinuation of heparin for variable
periods (2–5 days) with concomitant need of PRBCs transfu-
sion. None had circuit clotting during this period.
Secondary bacterial infections including ventilator associ-
ated pneumonia were the most common complications in our
patients and were relatively higher than that demonstrated in
other studies approaching 30–40% of cases [60].
5. Conclusions
ECMO can be introduced in highly specialized tertiary centers
in developing countries. Benchmarking against ELSO results
may help continuous quality improvements in starting ECMO
centers.
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